Acorda Therapeutics (ACOR) Tops Q2 EPS by 22c

Acorda Therapeutics (NASDAQ: ACOR) reported Q2 EPS of ($1.87), $0.22 better than the analyst estimate of ($2.09). Revenue for the quarter came in at $31.78 million versus the consensus estimate of $29.94 million.

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business
• Home Depot beats estimates, reaffirms fiscal 2026 guidance